APLS Pengajuan SEC - Apellis Pharmaceuticals, Inc.- Laporan Tahunan, Pernyataan Kuasa, Prospektus

Mga Batayang Estadistika

LEI	254900HS0ZFRXXSB9D42
CIK	1492422

SEC Filings

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Apellis Pharmaceuticals, Inc.

SEC Filings (Chronological Order)

Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.

July 31, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38276 APELLIS PHARMACEUTICALS, INC.
July 1, 2025	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 1, 2025 Apellis Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38276 27-1537290 (State or Other Jurisdiction of Incorporation) (Commiss
June 4, 2025	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 3, 2025 Apellis Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38276 27-1537290 (State or Other Jurisdiction of Incorporation) (Commiss
May 7, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38276 APELLIS PHARMACEUTICALS, INC.
May 7, 2025	EX-10.1	Separation Agreement, dated February 21, 2025, by and between Adam Townsend and the Registrant Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential.
April 23, 2025	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defini
April 23, 2025	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defini
April 21, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 17, 2025 Apellis Pharmaceut UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 17, 2025 Apellis Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38276 27-1537290 (State or Other Jurisdiction of Incorporation) (Commi
February 28, 2025	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-382
February 28, 2025	S-8	As filed with the Securities and Exchange Commission on February 28, 2025 As filed with the Securities and Exchange Commission on February 28, 2025 Registration No.
February 28, 2025	EX-21.1	Subsidiaries of the Registrant Exhibit 21.1 SUBSIDIARIES OF APELLIS PHARMACEUTICALS, INC. Subsidiary Jurisdiction of Incorporation or Organization Apellis Australia Pty Ltd. Australia Apellis Austria GmbH Austria Apellis Bermuda Ltd. Bermuda Apellis Canada Inc. Canada Apellis Cayman Holdings Limited Cayman Islands APL DEL Holdings LLC United States APL DEL Holdings II, LLC United States Apellis Europe B.V Netherlands Apellis Ge
February 28, 2025	EX-FILING FEES	Filing Fee Table. Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Apellis Pharmaceuticals, Inc.
February 10, 2025	EX-99	JOINT FILING AGREEMENT JOINT FILING AGREEMENT The undersigned hereby agree that this Schedule 13G (the “Schedule 13G”) with respect to the common stock of Apellis Pharmaceuticals, Inc.
January 13, 2025	EX-99.1	Apellis Highlights Commercial Growth and Strategic Priorities at 43rd Annual J.P. Morgan Healthcare Conference Exhibit 99.1 Apellis Highlights Commercial Growth and Strategic Priorities at 43rd Annual J.P. Morgan Healthcare Conference • Reports $709 million in preliminary1 full-year 2024 U.S. net product revenues • $611 million in SYFOVRE® U.S. net product revenues, including $167 million in 4Q 2024 • $98 million in EMPAVELI® U.S. net product revenues, including $23 million in 4Q 2024 • Expects submission
January 13, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 8, 2025 Apellis Pharmaceu UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 8, 2025 Apellis Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38276 27-1537290 (State or Other Jurisdiction of Incorporation) (Comm
November 22, 2024	SC 13G/A	APLS / Apellis Pharmaceuticals, Inc. / Deep Track Capital, LP Passive Investment SC 13G/A 1 deeptrack-apls111524a1.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Apellis Pharmaceuticals Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 03753U106 (CUSIP Number) November 20, 2024 (Date of Event Which Requires Filing of this Statement
November 22, 2024	SC 13G	APLS / Apellis Pharmaceuticals, Inc. / Deep Track Capital, LP Passive Investment SC 13G 1 deeptrack-apls111524.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Apellis Pharmaceuticals Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 03753U106 (CUSIP Number) November 15, 2024 (Date of Event Which Requires Filing of this Statement) Check
November 8, 2024	EX-99	JOINT FILING AGREEMENT EX-99 2 Rule13DJointFilingAgreement.htm JOINT FILING AGREEMENT JOINT FILING AGREEMENT The undersigned hereby agree that this Schedule 13G (the “Schedule 13G”) with respect to the common stock of Apellis Pharmaceuticals, Inc. is, and any additional amendment thereto signed by each of the undersigned shall be, filed on behalf of each undersigned pursuant to and in accordance with the provisions of 1
November 8, 2024	SC 13G/A	APLS / Apellis Pharmaceuticals, Inc. / WELLINGTON MANAGEMENT GROUP LLP - SEC SCHEDULE 13G Passive Investment SC 13G/A 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 7 )* Apellis Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 03753U106 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropr
November 5, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38276 APELLIS PHARMACEUTICALS, INC.
August 8, 2024	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2024 Apellis Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38276 27-1537290 (State or Other Jurisdiction of Incorporation) (Commi
August 1, 2024	EX-10.1	Financing Agreement, dated as of May 13, 2024, among the Registrants, as borrower, certain subsidiaries of the Registrant, as guarantors, various lenders from time to time party thereto, and Sixth Lending Partners, as administrative agent. Portions of this exhibit have been omitted pursuant to Item 601(b)(10)(iv) of Regulation S-K. Exhibit 10.1 Execution Version Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Double asterisks denote omissions. FINANCING AGREEMENT dated as of May 13, 2024 among APELLIS PHARMACEUTICALS, INC., as Borrower, CERTAIN SUBSIDIARIES OF BORROWER, as Guarantor
August 1, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38276 APELLIS PHARMACEUTICALS, INC.
June 5, 2024	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 5, 2024 Apellis Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38276 27-1537290 (State or Other Jurisdiction of Incorporation) (Commiss
May 14, 2024	8-K	Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2024 Apellis Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38276 27-1537290 (State or Other Jurisdiction of Incorporation) (Commiss
May 7, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38276 APELLIS PHARMACEUTICALS, INC.
April 26, 2024	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defini
April 26, 2024	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defini
February 29, 2024	10-K/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-3
February 27, 2024	EX-97.1	EX-97.1
February 27, 2024	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-38276 APELLIS PHARMAC
February 27, 2024	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Apellis Pharmaceuticals, Inc.
February 27, 2024	8-K	Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 27, 2024 Apellis Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38276 27-1537290 (State or Other Jurisdiction of Incorporation) (Co
February 27, 2024	EX-21.1	Subsidiaries of the Registrant Exhibit 21.1 SUBSIDIARIES OF APELLIS PHARMACEUTICALS, INC. Subsidiary Jurisdiction of Incorporation or Organization Apellis Australia Pty Ltd. Australia Apellis Austria GmbH Austria Apellis Bermuda Ltd. Bermuda Apellis Canada Inc. Canada Apellis Cayman Holdings Limited Cayman Islands APL DEL Holdings LLC United States APL DEL Holdings II, LLC United States Apellis Europe B.V Netherlands Apellis Ge
February 27, 2024	EX-97.1	Dodd-Frank Compensation Recovery Policy APELLIS PHARMACEUTICALS, INC. Dodd-Frank Compensation Recovery Policy This Compensation Recovery Policy (this “Policy”) is adopted by Apellis Pharmaceuticals, Inc. (the “Company”) in accordance with Nasdaq Listing Rule 5608 (“Rule 5608”), which implements Rule 10D-1 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”) (as promulgated pursuant to Section 954 of the Dodd-Frank
February 27, 2024	S-8	As filed with the Securities and Exchange Commission on February 27, 2024 As filed with the Securities and Exchange Commission on February 27, 2024 Registration No.
February 27, 2024	EX-99.1	Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results - Generated $397 million in full year 2023 revenues, including $275 million for SYFOVRE® (pegcetacoplan injection) and $91 million for EMPAVELI® (pegcetacoplan) - Str Exhibit 99.1 Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results - Generated $397 million in full year 2023 revenues, including $275 million for SYFOVRE® (pegcetacoplan injection) and $91 million for EMPAVELI® (pegcetacoplan) - Strong SYFOVRE launch, with more than 160,000 total doses (commercial and samples) distributed in 2023 - Topline data from Phase 3 VALIANT s
February 27, 2024	EX-10.28	Offer Letter, dated as of December 25, 20202, by and between the Registrant and Baumal Caroline 100 5th Avenue, 3rd Floor Waltham, MA 02451 P. 617.977.5700 Revised December 25, 2022 Caroline Baumal, M.D. 326 Highland Street West Newton, MA 02465 cbaumal@ gmail.com Dear Caroline: We are pleased to extend you an offer to join Apellis Pharmaceuticals, Inc. (“Apellis” or the “Company) as Chief Medical Officer. You will be responsible for developing and executing the Medical Affairs strategy in s
February 14, 2024	SC 13G/A	APLS / Apellis Pharmaceuticals, Inc. / EcoR1 Capital, LLC Passive Investment SC 13G/A 1 apls13ga.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1) Apellis Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 03753U106 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the ap
February 14, 2024	SC 13G/A	APLS / Apellis Pharmaceuticals, Inc. / Avoro Capital Advisors LLC - APELLIS PHARMACEUTICALS, INC. Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Apellis Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 03753U106 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pursuant
February 13, 2024	SC 13G/A	APLS / Apellis Pharmaceuticals, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 3)* Name of issuer: Apellis Pharmaceuticals Inc Title of Class of Securities: Common Stock CUSIP Number: 03753U106 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box to designate the rule pursuant to which this Schedule is
February 8, 2024	SC 13G/A	APLS / Apellis Pharmaceuticals, Inc. / WELLINGTON MANAGEMENT GROUP LLP - SEC SCHEDULE 13G Passive Investment SC 13G/A 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 6 )* Apellis Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 03753U106 (CUSIP Number) December 29, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropri
January 22, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 16, 2024 Apellis Pharmace UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 16, 2024 Apellis Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38276 27-1537290 (State or Other Jurisdiction of Incorporation) (Com
January 8, 2024	EX-99.1	Apellis Announces Preliminary Fourth Quarter and Full Year 2023 U.S. Net Product Revenues Exhibit 99.1 Apellis Announces Preliminary Fourth Quarter and Full Year 2023 U.S. Net Product Revenues • Approximately $114 million in preliminary fourth quarter SYFOVRE® revenue as strong launch continues • Approximately $24 million in preliminary fourth quarter EMPAVELI® revenue WALTHAM, Mass., January 8, 2024 (GLOBE NEWSWIRE) – Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced prelim
January 8, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 8, 2024 Apellis Pharmaceu UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 8, 2024 Apellis Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38276 27-1537290 (State or Other Jurisdiction of Incorporation) (Comm
December 14, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 14, 2023 Apellis Pharmac UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 14, 2023 Apellis Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38276 27-1537290 (State or Other Jurisdiction of Incorporation) (Co
December 1, 2023	8-K	Regulation FD Disclosure UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 30, 2023 Apellis Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38276 27-1537290 (State or Other Jurisdiction of Incorporation) (Co
November 20, 2023	CORRESP	November 20, 2023 November 20, 2023 By EDGAR Submission U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attention: Sasha Parikh, Vanessa Robertson Re: Apellis Pharmaceuticals, Inc. Form 10-K for the Fiscal Year Ended December 31, 2022 Filed February 21, 2023 Form 10-Q for the period ended September 30, 2023 Filed November 1, 2
November 1, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38276 APELLIS PHARMACEUTICALS, INC.
November 1, 2023	EX-1.1	Sales Agreement, dated as of November 1, 2023 by and between Apellis Pharmaceuticals, Inc. and Cowen and Company, LLC. Exhibit 1.1 SALES AGREEMENT November 1, 2023 COWEN AND COMPANY, LLC 599 Lexington Avenue New York, New York 10022 Ladies and Gentlemen: Apellis Pharmaceuticals, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Cowen and Company, LLC (the “Manager”) as follows: 1. Description of Shares. The Company proposes to issue and sell through or to the Manager, as
November 1, 2023	424B5	Up to $300,000,000 Common Stock Table of Contents Filed pursuant to Rule 424(b)(5) Registration No: 333-269899 PROSPECTUS SUPPLEMENT (To Prospectus Dated February 22, 2023) Up to $300,000,000 Common Stock We have entered into a Sales Agreement, or the sales agreement, with Cowen and Company, LLC, or TD Cowen, dated November 1, 2023, relating to the sale of shares of our common stock offered by this prospectus supplement and the accompanying prospectus.
November 1, 2023	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 31, 2023 Apellis Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38276 27-1537290 (State or Other Jurisdiction of Incorporation) (Com
November 1, 2023	EX-FILING FEES	Calculation of Filing Fee Tables (Form Type) Apellis Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1—Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forwar Exhibit 107 Calculation of Filing Fee Tables 424(b)(5) (Form Type) Apellis Pharmaceuticals, Inc.
October 5, 2023	EX-99.1	Apellis Announces Preliminary U.S. Net Revenues of Approximately $74 Million for SYFOVRE® (pegcetacoplan injection) in the Third Quarter of 2023 Exhibit 99.1 Apellis Announces Preliminary U.S. Net Revenues of Approximately $74 Million for SYFOVRE® (pegcetacoplan injection) in the Third Quarter of 2023 • Continued strong demand, with more than 100,000 vials (commercial and sample) distributed to date; growth in week-over-week demand returned starting in August • Permanent J-code effective as of October 1, and more than 95% of all Medicare p
October 5, 2023	8-K	Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 5, 2023 Apellis Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38276 27-1537290 (State or Other Jurisdiction of Incorporation) (Comm
September 8, 2023	SC 13G/A	APLS / Apellis Pharmaceuticals Inc / WELLINGTON MANAGEMENT GROUP LLP - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 5 )* Apellis Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 03753U106 (CUSIP Number) August 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which
August 29, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 28, 2023 Apellis Pharmaceu UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 28, 2023 Apellis Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38276 27-1537290 (State or Other Jurisdiction of Incorporation) (Comm
August 22, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 22, 2023 Apellis Pharmaceu UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 22, 2023 Apellis Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38276 27-1537290 (State or Other Jurisdiction of Incorporation) (Comm
July 31, 2023	EX-99.1	Apellis Pharmaceuticals Reports Second Quarter 2023 Financial Results EX-99.1 Exhibit 99.1 Apellis Pharmaceuticals Reports Second Quarter 2023 Financial Results • Generated total U.S. net product revenues of $89.6 million, including $67.3 million for SYFOVRE® (pegcetacoplan injection) and $22.3 million for EMPAVELI® (pegcetacoplan) • SYFOVRE reduced nonsubfoveal GA lesion growth by up to 45% between Months 24-30 compared to projected sham in the GALE long-term exten
July 31, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 31, 2023 Apellis Pharmaceuti UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 31, 2023 Apellis Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38276 27-1537290 (State or Other Jurisdiction of Incorporation) (Commis
July 31, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38276 APELLIS PHARMACEUTICALS, INC.
July 18, 2023	SC 13G	APLS / Apellis Pharmaceuticals Inc / EcoR1 Capital, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. ) Apellis Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 03753U106 (CUSIP Number) July 18, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate th
July 17, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 15, 2023 Apellis Pharmaceuti UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 15, 2023 Apellis Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38276 27-1537290 (State or Other Jurisdiction of Incorporation) (Commis
June 1, 2023	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 1, 2023 Apellis Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38276 27-1537290 (State or Other Jurisdiction of Incorporation) (Commiss
May 4, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38276 APELLIS PHARMACEUTICALS, INC.
April 21, 2023	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defini
April 21, 2023	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defini
March 15, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 15, 2023 Apellis Pharmaceut UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 15, 2023 Apellis Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38276 27-1537290 (State or Other Jurisdiction of Incorporation) (Commi
February 24, 2023	EX-1.1	Underwriting Agreement, dated February 22, 2023, by and among the Company and J.P. Morgan Securities LLC, Goldman Sachs & Co. LLC and Evercore Group L.L.C. Exhibit 1.1 Apellis Pharmaceuticals, Inc. 3,174,603 Shares of Common Stock ($0.0001 par value per share) Pre-Funded Warrants to Purchase 2,380,956 Shares of Common Stock Underwriting Agreement New York, New York February 22, 2023 J.P. Morgan Securities LLC Goldman Sachs & Co. LLC Evercore Group L.L.C. As Representatives of the several Underwriters c/o J.P. Morgan Securities LLC 383 Madison Avenue
February 24, 2023	424B5	Raymond James 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration Nos. 333-269899 Prospectus supplement (To Prospectus Dated February 22, 2023) 3,174,603 shares of common stock Pre-funded warrants to purchase up to 2,380,956 shares of common stock We are offering 3,174,603 shares of our common stock and, in lieu of common stock to investors who so choose, pre-funded warrants to purchase up to
February 24, 2023	EX-FILING FEES	Calculation of Filing Fee Tables (Form Type) Apellis Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forwa EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables 424(b)(5) (Form Type) Apellis Pharmaceuticals, Inc.
February 24, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 22, 2023 Apellis Pharmac UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 22, 2023 Apellis Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38276 27-1537290 (State or Other Jurisdiction of Incorporation) (Co
February 24, 2023	EX-99.1	Apellis Pharmaceuticals Announces Pricing of Public Offering of Common Stock and EX-99.1 Exhibit 99.1 Apellis Pharmaceuticals Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants WALTHAM, Mass., February 22, 2023 (GLOBE NEWSWIRE) – Apellis Pharmaceuticals, Inc., (Nasdaq:APLS), a global biopharmaceutical company and leader in complement, today announced the pricing of its underwritten public offering of 3,174,603 shares of its common stock at a public of
February 24, 2023	EX-4.1	Form of Pre-Funded Warrant EX-4.1 Exhibit 4.1 APELLIS PHARMACEUTICALS, INC. FORM OF PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK Warrant No. [ ] Original Issue Date: [ ], 2023 Number of Shares: [ ] (subject to adjustment) Apellis Pharmaceuticals Inc., a Delaware corporation (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [ ], or its pe
February 22, 2023	EX-4.5	Form of Senior Indenture EX-4.5 Exhibit 4.5 APELLIS PHARMACEUTICALS, INC. and Trustee INDENTURE Dated as of SENIOR DEBT SECURITIES CROSS-REFERENCE TABLE1 Section of Trust Indenture Act of 1939, as amended Section of Indenture 310(a) 6.09 310(b) 6.08 6.10 310(c) Inapplicable 311(a) 6.13 311(b) 6.13 311(c) Inapplicable 312(a) 4.01 4.04 312(b) 4.04(c) 312(c) 4.04(c) 313(a) 4.03 313(b) 4.03 313(c) 4.03 313(d) 4.03 314(a) 4.02
February 22, 2023	EX-4.6	Form of Subordinated Indenture EX-4.6 Exhibit 4.6 APELLIS PHARMACEUTICALS, INC. and Trustee INDENTURE Dated as of SUBORDINATED DEBT SECURITIES CROSS-REFERENCE TABLE 1 Section of Trust Indenture Act of 1939, as amended Section of Indenture 310(a) 6.09 310(b) 6.08 6.10 310(c) Inapplicable 311(a) 6.13 311(b) 6.13 311(c) Inapplicable 312(a) 4.01 4.04 312(b) 4.04(c) 312(c) 4.04(c) 313(a) 4.03 313(b) 4.03 313(c) 4.03 313(d) 4.03 314(
February 22, 2023	S-3ASR	As filed with the Securities and Exchange Commission on February 22, 2023 S-3ASR Table of Contents As filed with the Securities and Exchange Commission on February 22, 2023 Registration No.
February 22, 2023	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Apellis Pharmaceuticals, Inc.
February 22, 2023	EX-4.8	Form of Subordinated Note EX-4.8 Exhibit 4.8 Form of Subordinated Note (FACE OF SECURITY) [Each Global Security shall bear substantially the following legend: UNLESS AND UNTIL IT IS EXCHANGED IN WHOLE OR IN PART FOR SECURITIES IN DEFINITIVE REGISTERED FORM, THIS SECURITY MAY NOT BE TRANSFERRED EXCEPT AS A WHOLE BY THE DEPOSITARY TO A NOMINEE OF THE DEPOSITARY OR BY A NOMINEE OF THE DEPOSITARY TO THE DEPOSITARY OR ANOTHER N
February 22, 2023	EX-4.7	Form of Senior Note EX-4.7 Exhibit 4.7 Form of Senior Note (FACE OF SECURITY) [Each Global Security shall bear substantially the following legend: UNLESS AND UNTIL IT IS EXCHANGED IN WHOLE OR IN PART FOR SECURITIES IN DEFINITIVE REGISTERED FORM, THIS SECURITY MAY NOT BE TRANSFERRED EXCEPT AS A WHOLE BY THE DEPOSITARY TO A NOMINEE OF THE DEPOSITARY OR BY A NOMINEE OF THE DEPOSITARY TO THE DEPOSITARY OR ANOTHER NOMINEE
February 22, 2023	424B5	Raymond James 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration Nos. 333-269899 The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these securities has been filed with the Securities and Exchange Commission and is effective. This preliminary prospectus supplement and the accompanying prospectus are not an offer t
February 21, 2023	EX-FILING FEES	Filing Fee Table EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Apellis Pharmaceuticals, Inc.
February 21, 2023	EX-21	Subsidiaries of the Registrant Exhibit 21.1 SUBSIDIARIES OF APELLIS PHARMACEUTICALS, INC. Subsidiary Jurisdiction of Incorporation or Organization Apellis Australia Pty Ltd. Australia Apellis Bermuda Ltd. Bermuda Apellis Cayman Holdings Limited Cayman Islands APL DEL Holdings LLC United States Apellis Canada Inc. Canada APL DEL Holdings II, LLC United States Apellis Germany GmbH Germany Apellis France S.A.S. France Apellis Irel
February 21, 2023	EX-10	Form of Restricted Stock Unit Agreement under the 2017 Stock Incentive Plan APELLIS PHARMACEUTICALS, INC. RESTRICTED STOCK UNIT AWARD AGREEMENT (the “Agreement”) Apellis Pharmaceuticals, Inc. (the “Company”) has selected you to receive an award of restricted stock units (“RSUs”) pursuant to the Company’s 2017 Stock Incentive Plan (the “Plan”). The terms and conditions attached hereto are also a part hereof. Terms used in this Agreement which are not defined in this Agreem
February 21, 2023	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-38276 APELLIS PHARMAC
February 21, 2023	S-8	As filed with the Securities and Exchange Commission on February 21, 2023 S-8 As filed with the Securities and Exchange Commission on February 21, 2023 Registration No.
February 14, 2023	SC 13G/A	APLS / Apellis Pharmaceuticals Inc / Avoro Capital Advisors LLC - APELLIS PHARMACEUTICALS, INC. Passive Investment SC 13G/A 1 p23-0266sc13ga.htm APELLIS PHARMACEUTICALS, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Apellis Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 03753U106 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of This Statemen
February 9, 2023	SC 13G/A	APLS / Apellis Pharmaceuticals Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 2)* Name of issuer: Apellis Pharmaceuticals Inc. Title of Class of Securities: Common Stock CUSIP Number: 03753U106 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to designate the rule pursuant to which this Schedule is
February 6, 2023	SC 13G/A	APLS / Apellis Pharmaceuticals Inc / WELLINGTON MANAGEMENT GROUP LLP - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4 )* Apellis Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 03753U106 (CUSIP Number) December 30, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to whi
January 9, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 9, 2023 Apellis Pharmaceu UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 9, 2023 Apellis Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38276 27-1537290 (State or Other Jurisdiction of Incorporation) (Comm
January 9, 2023	EX-99.1	Excerpt from corporate presentation dated January 2023 EX-99.1 2 d436376dex991.htm EX-99.1 2022 was a transformational year Submitted NDA to U.S. FDA Submitted MAA to EMA U.S. commercial preparations complete; deployed ~100 field-based employees mid-2022 Appointed leading retina specialist, Dr. Caroline Baumal as Chief Medical Officer (effective Q1 2023) ~$65 million1 in U.S. net product sales Submitted sNDA for PRINCE & 48-week PEGASUS data Submitted
January 5, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 3, 2023 Apellis Pharmaceu UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 3, 2023 Apellis Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38276 27-1537290 (State or Other Jurisdiction of Incorporation) (Comm
November 7, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38276 APELLIS PHARMACEUTICALS, INC.
August 24, 2022	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 24, 2022 Apellis Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38276 27-1537290 (State or Other Jurisdiction of Incorporation) (Comm
August 8, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38276 APELLIS PHARMACEUTICALS, INC.
August 2, 2022	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 28, 2022 Apellis Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38276 27-1537290 (State or Other Jurisdiction of Incorporation) (Commis
August 2, 2022	EX-10.1	Form of Exchange Agreement Exhibit 10.1 Exchange Agreement July 28, 2022 Apellis Pharmaceuticals, Inc. 3.500% Convertible Senior Notes due 2026 The undersigned investor (the “Investor”), for itself and on behalf of the beneficial owners listed on Exhibit A hereto (“Accounts”) for whom the Investor holds contractual and investment authority (each, including the Investor if it is a party exchanging Notes (as defined below), a
July 27, 2022	EX-10.1	Form of Exchange Agreement Exhibit 10.1 Exchange Agreement July 26, 2022 Apellis Pharmaceuticals, Inc. 3.500% Convertible Senior Notes due 2026 The undersigned investor (the ?Investor?), for itself and on behalf of the beneficial owners listed on Exhibit A hereto (?Accounts?) for whom the Investor holds contractual and investment authority (each, including the Investor if it is a party exchanging Notes (as defined below), a
July 27, 2022	EX-99.1	Apellis Announces Agreements to Exchange Approximately $75.6 Million in Principal Amount of Its 3.500% Convertible Senior Notes Due 2026 for Common Stock Exhibit 99.1 Apellis Announces Agreements to Exchange Approximately $75.6 Million in Principal Amount of Its 3.500% Convertible Senior Notes Due 2026 for Common Stock July 27, 2022 WALTHAM, Mass., July 27, 2022 (GLOBE NEWSWIRE) ? Apellis Pharmaceuticals, Inc. (Nasdaq:APLS), a global biopharmaceutical company and leader in complement, today announced that it has entered into separate, privately neg
July 27, 2022	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 26, 2022 Apellis Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38276 27-1537290 (State or Other Jurisdiction of Incorporation) (Commis
July 19, 2022	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 19, 2022 Apellis Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38276 27-1537290 (State or Other Jurisdiction of Incorporation) (Commis
June 2, 2022	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 1, 2022 Apellis Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38276 27-1537290 (State or Other Jurisdiction of Incorporation) (Commiss
May 4, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38276 APELLIS PHARMACEUTICALS, INC.
April 20, 2022	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin
April 20, 2022	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) DEF 14A 1 d296528ddef14a.htm DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Com
March 25, 2022	EX-FILING FEES	Calculation of Filing Fee Tables (Form Type) Apellis Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1—Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forwar EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables 424(b)(5) (Form Type) Apellis Pharmaceuticals, Inc.
March 25, 2022	EX-1.1	Underwriting Agreement, dated March 23, 2022, by and among the Company and J.P. Morgan Securities LLC, Goldman Sachs & Co. LLC and Evercore Group L.L.C.,. Exhibit 1.1 EXECUTION VERSION Apellis Pharmaceuticals, Inc. 7,446,809 Shares Common Stock ($0.0001 par value per share) Underwriting Agreement New York, New York March 23, 2022 J.P. Morgan Securities LLC Goldman Sachs & Co. LLC Evercore Group L.L.C. As Representatives of the several Underwriters, c/o J.P. Morgan Securities LLC 383 Madison Avenue New York, New York 10179 c/o Goldman Sachs & Co. LLC
March 25, 2022	424B5	Oppenheimer & Co. Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-235830 Prospectus supplement (To Prospectus Dated January 7, 2020) 7,446,809 Shares Common stock We are offering 7,446,809 shares of our common stock in this offering. Our common stock is listed on the Nasdaq Global Select Market under the symbol ?APLS.? The last reported sale price of our common stock on the Nasdaq Global Sel
March 25, 2022	EX-99.1	Apellis Pharmaceuticals Announces Pricing of Public Offering of Common Stock Exhibit 99.1 Apellis Pharmaceuticals Announces Pricing of Public Offering of Common Stock WALTHAM, Mass., March 24, 2022 (GLOBE NEWSWIRE) ? Apellis Pharmaceuticals, Inc., (Nasdaq:APLS), a global biopharmaceutical company and leader in complement, today announced the pricing of its underwritten public offering of 7,446,809 shares of its common stock at a public offering price of $47.00 per share, f
March 25, 2022	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 23, 2022 Apellis Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38276 27-1537290 (State or Other Jurisdiction of Incorporation) (Commi
March 23, 2022	424B5	Apellis Pharmaceuticals, Inc. 100 Fifth Avenue Waltham, Massachusetts 02451 (617) 977-5700 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-235830 The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these securities has been filed with the Securities and Exchange Commission and is effective. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell
March 16, 2022	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 16, 2022 Apellis Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38276 27-1537290 (State or Other Jurisdiction of Incorporation) (Commi
February 28, 2022	EX-10.29	Offer Letter, dated as of April 20, 2020, by and between the Registrant and Nur Nicholson Exhibit 10.29 6400 Westwind Way, Suite A Crestwood, KY, 40014 P:(502) 241-4114 April 20, 2020 Nur Nicholson VIA EMAIL Dear Nur: We are pleased to extend you an offer to join Apellis Pharmaceuticals, Inc. (?Apellis? or the ?Company?) as our Chief Technical Officer. You will be responsible for developing and executing our manufacturing, supply chain, and technical development strategy in support of
February 28, 2022	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Apellis Pharmaceuticals, Inc.
February 28, 2022	S-8	As filed with the Securities and Exchange Commission on February 28, 2022 As filed with the Securities and Exchange Commission on February 28, 2022 Registration No.
February 28, 2022	EX-10.10	Summary of Non-Employee Director Compensation Program Exhibit 10.10 SUMMARY OF NON-EMPLOYEE DIRECTOR COMPENSATION PROGRAM Apellis Pharmaceuticals, Inc. (the ?Company?) will maintain the following non-employee director compensation program, effective January 1, 2022: Cash Compensation. Each non-employee director will receive a cash retainer for service on the board of directors (the ?Board?) and for service on each committee on which the director is a
February 28, 2022	EX-4.4	Exhibit 4.4 Exhibit 4.4 DESCRIPTION OF SECURITIES REGISTERED UNDER SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following description of the common stock, par value $0.0001 per share (the ?Common Stock?), of Apellis Pharmaceuticals, Inc. (?us,? ?our,? ?we? or the ?Company?), which is the only security of the Company registered under Section 12 of the Securities Exchange Act of 1934, as amended (the ?
February 28, 2022	EX-21.1	Subsidiaries of the Registrant Exhibit 21.1 SUBSIDIARIES OF APELLIS PHARMACEUTICALS, INC. Subsidiary Jurisdiction of Incorporation or Organization Apellis Australia Pty Ltd. Australia Apellis Bermuda Ltd. Bermuda Apellis Cayman Holdings Limited Cayman Islands APL DEL Holdings LLC United States APL DEL Holdings II, LLC United States Apellis Germany GmbH Germany Apellis France S.A.S. France Apellis Ireland Ltd. Ireland Apellis Ne
February 28, 2022	10-K	correctco UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K correctco UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-38276 APELL
February 28, 2022	EX-10.30	Offer Letter, dated as of November 16, 2018, by and between the Registrant and Adam Townsend Exhibit 10.30 6400 Westwind Way, Suite A Crestwood, KY, 40014 P:(502) 241-4114 November 16, 2018 Adam Townsend VIA EMAIL Dear Adam: We are pleased to extend you an offer to join Apellis Pharmaceuticals as Chief Commercial Officer. Subject to satisfaction of the conditions described in this letter, you will begin employment on November 16, 2018 (or another mutually acceptable start date). You agree
February 14, 2022	SC 13G/A	APLS / Apellis Pharmaceuticals Inc / Morningside Venture Investments Ltd - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 5)* APELLIS PHARMACEUTICALS, INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 03753U 106 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to des
February 14, 2022	SC 13G/A	APLS / Apellis Pharmaceuticals Inc / HILLHOUSE CAPITAL ADVISORS, LTD. - APELLIS PHARMACEUTICALS, INC. Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 4)* Apellis Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value of $0.0001 per share (Title of Class of Securities) 03753U106 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the r
February 14, 2022	EX-99.1	JOINT FILING AGREEMENT EXHIBIT 99.1 JOINT FILING AGREEMENT The undersigned, being duly authorized thereunder, hereby execute this agreement as an exhibit to this Schedule 13G to evidence the agreement of the below-named parties, in accordance with the rules promulgated pursuant to the Securities Exchange Act of 1934, to file this Schedule 13G (including amendments thereto) jointly on behalf of each such party. MORNINGSI
February 11, 2022	SC 13G	APLS / Apellis Pharmaceuticals Inc / Avoro Capital Advisors LLC - APELLIS PHARMACEUTICALS, INC. Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Apellis Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 03753U106 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pursuant to
February 9, 2022	SC 13G/A	APLS / Apellis Pharmaceuticals Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 1)* Name of issuer: Apellis Pharmaceuticals Inc. Title of Class of Securities: Common Stock CUSIP Number: 03753U106 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule is
February 4, 2022	SC 13G/A	APLS / Apellis Pharmaceuticals Inc / WELLINGTON MANAGEMENT GROUP LLP - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3 )* Apellis Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 03753U106 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to whi
January 20, 2022	EX-1.1	Open Market Sale AgreementSM, dated as of January 20, 2022, by and between Apellis Pharmaceuticals, Inc. and Jefferies LLC Exhibit 1.1 Execution Version OPEN MARKET SALE AGREEMENTSM January 20, 2022 JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: Apellis Pharmaceuticals, Inc., a Delaware corporation (the ?Company?), confirms its agreement (this ?Agreement?) with Jefferies LLC (the ?Manager?) as follows: 1. Description of Shares. The Company proposes to issue and sell through or to the M
January 20, 2022	8-K	Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 20, 2022 Apellis Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38276 27-1537290 (State or Other Jurisdiction of Incorporation) (Com
January 20, 2022	424B5	CALCULATION OF REGISTRATION FEE Title of Each Class of Securities to be Registered Proposed Maximum Aggregate Offering Price Amount of Registration Fee(1) Common Stock, par value $0.0001 per share $300,000,000 $27,810 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-235830 CALCULATION OF REGISTRATION FEE Title of Each Class of Securities to be Registered Proposed Maximum Aggregate Offering Price Amount of Registration Fee(1) Common Stock, par value $0.0001 per share $300,000,000 $27,810 (1) Calculated in accordance with Rules 457(o) under the Securities Act of 1933, as amended. This ?Calc
January 10, 2022	EX-99.1	EMPAVELI commercial launch off to a strong start As of December 31, 2021: >95% patient compliance rate >125 start forms submitted FY 2021 U.S. Net Product Sales >75% of C5 switches from Ultomiris ~$15 Million1 • C5 inhibitor switch patients are major Exhibit 99.1 EMPAVELI commercial launch off to a strong start As of December 31, 2021: >95% patient compliance rate >125 start forms submitted FY 2021 U.S. Net Product Sales >75% of C5 switches from Ultomiris ~$15 Million1 ? C5 inhibitor switch patients are majority of new EMPAVELI starts Zero cases of meningococcal infection 1. Estimated 2021 EMPAVELI U.S. net product sales are unaudited, prelimi
January 10, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 10, 2022 Apellis Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38276 27-1537290 (State or Other Jurisdiction of Incorporation) (Com
November 17, 2021	424B5	CALCULATION OF REGISTRATION FEE Title of Each Class of Securities Offered Amount to be Registered(1) Maximum Offering Price Per Unit Maximum Aggregate Offering Price(1) Amount of Registration Fee(2) Common Stock, par value $0.0001 per share 10,062,50 Table of Contents CALCULATION OF REGISTRATION FEE Title of Each Class of Securities Offered Amount to be Registered(1) Maximum Offering Price Per Unit Maximum Aggregate Offering Price(1) Amount of Registration Fee(2) Common Stock, par value $0.
November 17, 2021	EX-1.1	Underwriting Agreement, dated November 15, 2021, by and among the Company and J.P. Morgan Securities LLC, Goldman Sachs & Co. LLC and Evercore Group L.L.C. Exhibit 1.1 EXECUTION VERSION Apellis Pharmaceuticals, Inc. 8,750,000 Shares Common Stock ($0.0001 par value per share) Underwriting Agreement New York, New York November 15, 2021 J.P. Morgan Securities LLC Goldman Sachs & Co. LLC Evercore Group L.L.C. As Representatives of the several Underwriters, c/o J.P. Morgan Securities LLC 383 Madison Avenue New York, New York 10179 c/o Goldman Sachs & Co.
November 17, 2021	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 15, 2021 Apellis Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38276 27-1537290 (State or Other Jurisdiction of Incorporation) (Co
November 17, 2021	EX-99.1	Apellis Pharmaceuticals Announces Pricing of Public Offering of Common Stock Exhibit 99.1 Apellis Pharmaceuticals Announces Pricing of Public Offering of Common Stock WALTHAM, Mass., Nov. 16, 2021 (GLOBE NEWSWIRE) ? Apellis Pharmaceuticals, Inc., (Nasdaq:APLS), a global biopharmaceutical company and leader in complement, today announced the pricing of its underwritten public offering of 8,750,000 shares of its common stock at a public offering price of $40.00 per share, fo
November 15, 2021	424B5	Apellis Pharmaceuticals, Inc. 100 Fifth Avenue Waltham, Massachusetts 02451 (617) 977-5700 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-235830 The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these securities has been filed with the Securities and Exchange Commission and is effective. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell
November 8, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38276 APELLIS PHARMACEUTICALS, INC.
September 9, 2021	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 9, 2021 Apellis Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38276 27-1537290 (State or Other Jurisdiction of Incorporation) (Co
August 30, 2021	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 24, 2021 Apellis Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38276 27-1537290 (State or Other Jurisdiction of Incorporation) (Comm
August 19, 2021	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 13, 2021 Apellis Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38276 27-1537290 (State or Other Jurisdiction of Incorporation) (Comm
August 9, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38276 APELLIS PHARMACEUTICALS, INC.
July 26, 2021	EX-99.1	Apellis Announces Closing of Previously Announced Exchanges of Approximately $201.1 Million in Principal Amount of Its 3.500% Convertible Senior Notes Due 2026 for Common Stock Exhibit 99.1 Apellis Announces Closing of Previously Announced Exchanges of Approximately $201.1 Million in Principal Amount of Its 3.500% Convertible Senior Notes Due 2026 for Common Stock July 26, 2021 WALTHAM, Mass., July 26, 2021 (GLOBE NEWSWIRE) ? Apellis Pharmaceuticals, Inc. (Nasdaq:APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced the closing of
July 26, 2021	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 23, 2021 Apellis Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38276 27-1537290 (State or Other Jurisdiction of Incorporation) (Commis
July 8, 2021	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 7, 2021 Apellis Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38276 27-1537290 (State or Other Jurisdiction of Incorporation) (Commiss
July 8, 2021	EX-99.1	Apellis Announces Agreements to Exchange Approximately $198.6 Million in Principal Amount of Its 3.500% Convertible Senior Notes Due 2026 for Common Stock Exhibit 99.1 Apellis Announces Agreements to Exchange Approximately $198.6 Million in Principal Amount of Its 3.500% Convertible Senior Notes Due 2026 for Common Stock July 7, 2021 WALTHAM, Mass., July 7, 2021 (GLOBE NEWSWIRE) ? Apellis Pharmaceuticals, Inc. (Nasdaq:APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that it has entered into separate, pri
July 8, 2021	EX-10.1	Form of Exchange Agreement Exhibit 10.1 Exchange Agreement July 7, 2021 Apellis Pharmaceuticals, Inc. 3.500% Convertible Senior Notes due 2026 The undersigned investor (the ?Investor?), for itself and on behalf of the beneficial owners listed on Exhibit A hereto (?Accounts?) for whom the Investor holds contractual and investment authority (each, including the Investor if it is a party exchanging Notes (as defined below), an
June 30, 2021	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 30, 2021 Apellis Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38276 27-1537290 (State or Other Jurisdiction of Incorporation) (Commis
June 1, 2021	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 1, 2021 Apellis Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38276 27-1537290 (State or Other Jurisdiction of Incorporation) (Commiss
April 28, 2021	10-Q	Quarterly Report - 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38276 APELLIS PHARMACEUTICALS, INC.
April 28, 2021	EX-10.1	Amended and Restated Commercial Supply Agreement, dated March 10, 2021, by and between the Registrant, Apellis Switzerland GmbH and NOF Corporation Exhibit 10.1 Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Double asterisks denote omissions. AMENDED AND RESTATED SUPPLY AGREEMENT by and between Apellis Pharmaceuticals, Inc., together with APELLIS switzerland gmbh and NOF CORPORATION This AMENDED AND
April 22, 2021	DEF 14A	definitive proxy statement Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14
April 22, 2021	DEFA14A	- DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin
March 11, 2021	8-K	Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2021 Apellis Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38276 27-1537290 (State or Other Jurisdiction of Incorporation) (Commi
February 25, 2021	10-K	Annual Report - 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-38276 APELLIS PHARMAC
February 25, 2021	S-8	- S-8 As filed with the Securities and Exchange Commission on February 25, 2021 Registration No.
February 25, 2021	EX-10.26	Commercial Supply Agreement, dated December 30, 2020, by and between the Registrant and Bachem Americas, Inc. Exhibit 10.26 Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) would likely cause competitive harm to the Company, if publicly disclosed. Double asterisks denote omissions. Commercial SUPPLY AGREEMENT This Commercial Supply Agreement (this ?Agreement?) is made effective as of January 1, 2021(the ?Effective Date?) by and between Apellis
February 25, 2021	EX-10.17	Fourth Amendment to Lease, dated November 13, 2020, by and between Registrant and NWALP PHOP Property Owner LLC. Exhibit 10.17 FOURTH AMENDMENT TO LEASE This FOURTH AMENDMENT TO LEASE (this ?Amendment?) is entered into this 13th day of November, 2020 (the ?Effective Date?) by and between NWALP PHOP Property Owner LLC, a Delaware limited liability company (the ?Landlord?), and Apellis Pharmaceuticals, Inc., a Delaware corporation (the ?Tenant?). W I T N E S S E T H: WHEREAS, the Landlord and the Tenant entere
February 25, 2021	EX-21.1	Subsidiaries of the Registrant Exhibit 21.1 SUBSIDIARIES OF APELLIS PHARMACEUTICALS, INC. Subsidiary Jurisdiction of Incorporation or Organization Apellis Australia Pty Ltd. Australia Apellis Bermuda Ltd Bermuda APL DEL Holdings LLC United States Apellis Germany GmbH Germany Apellis Ireland Ltd. Ireland Apellis Netherlands, B.V. Netherlands Apellis Switzerland GmbH Switzerland Apellis U.K. Limited United Kingdom Apellis MA Secu
February 25, 2021	EX-10.25	Collaboration and License Agreement, dated October 27, 2020, by and among, the Registrant, Apellis Switzerland GmbH, APL DEL holdings, LLC and Swedish Orphan Biovitrum AB (publ) Exhibit 10.25 Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) would likely cause competitive harm to the Company, if publicly disclosed. Double asterisks denote omissions. COLLABORATION AND LICENSE AGREEMENT by and among APELLIS SWITZERLAND GMBH APELLIS PHARMACEUTICALS, INC. APL DEL HOLDINGS, LLC and Swedish Orphan Biovitrum AB (publ)
February 25, 2021	EX-4.4	Exhibit 4.4 Exhibit 4.4 DESCRIPTION OF SECURITIES REGISTERED UNDER SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following description of the common stock, par value $0.0001 per share (the ?Common Stock?), of Apellis Pharmaceuticals, Inc. (?us,? ?our,? ?we? or the ?Company?), which is the only security of the Company registered under Section 12 of the Securities Exchange Act of 1934, as amended (the ?
February 16, 2021	SC 13G/A	Apellis Pharmaceuticals, Inc. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 3)* Apellis Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value of $0.0001 per share (Title of Class of Securities) 03753U106 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the r
February 16, 2021	EX-99.1	JOINT FILING AGREEMENT EXHIBIT 99.1 JOINT FILING AGREEMENT The undersigned, being duly authorized thereunder, hereby execute this agreement as an exhibit to this Schedule 13G to evidence the agreement of the below-named parties, in accordance with the rules promulgated pursuant to the Securities Exchange Act of 1934, to file this Schedule 13G (including amendments thereto) jointly on behalf of each such party. MORNINGSI
February 16, 2021	SC 13G/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 4)* APELLIS PHARMACEUTICALS, INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Cla UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 4)* APELLIS PHARMACEUTICALS, INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 03753U 106 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to des
February 10, 2021	SC 13G	SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 Name of issuer: Apellis Pharmaceuticals Inc. Title of Class of Securities: Common Stock CUSIP Number: 03753U106 Date of Event Which Requires Filing of this Statement: December 31, 2020 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule 13d-1
February 3, 2021	SC 13G/A	SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2 )* Apellis Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 03753U106 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to whi
January 26, 2021	EX-99.1	Apellis Announces Closing of Previously Announced Exchanges of Approximately $126.1 Million in Principal Amount of Its 3.500% Convertible Senior Notes Due 2026 for Common Stock EX-99.1 Exhibit 99.1 Apellis Announces Closing of Previously Announced Exchanges of Approximately $126.1 Million in Principal Amount of Its 3.500% Convertible Senior Notes Due 2026 for Common Stock January 26, 2021 WALTHAM, Mass., January 26, 2021 (GLOBE NEWSWIRE) — Apellis Pharmaceuticals, Inc. (Nasdaq:APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced
January 26, 2021	8-K	Financial Statements and Exhibits, Other Events - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 26, 2021 Apellis Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38276 27-1537290 (State or Other Jurisdiction of Incorporation) (Com
January 7, 2021	EX-10.1	Form of Exchange Agreement EX-10.1 2 d67311dex101.htm EX-10.1 Exhibit 10.1 Exchange Agreement January 6, 2021 Apellis Pharmaceuticals, Inc. 3.500% Convertible Senior Notes due 2026 The undersigned investor (the “Investor”), for itself and on behalf of the beneficial owners listed on Exhibit A hereto (“Accounts”) for whom the Investor holds contractual and investment authority (each, including the Investor if it is a party e
January 7, 2021	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 6, 2021 Apellis Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38276 27-1537290 (State or Other Jurisdiction of Incorporation) (Comm
January 7, 2021	EX-99.1	Apellis Announces Agreements to Exchange Approximately $107.5 Million in Principal Amount of Its 3.500% Convertible Senior Notes Due 2026 for Common Stock EX-99.1 3 d67311dex991.htm EX-99.1 Exhibit 99.1 Apellis Announces Agreements to Exchange Approximately $107.5 Million in Principal Amount of Its 3.500% Convertible Senior Notes Due 2026 for Common Stock January 7, 2021 WALTHAM, Mass., January 7, 2021 (GLOBE NEWSWIRE) — Apellis Pharmaceuticals, Inc. (Nasdaq:APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announc
January 4, 2021	8-K	Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 30, 2020 Apellis Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38276 27-1537290 (State or Other Jurisdiction of Incorporation) (Co
November 2, 2020	EX-10.2	Amendment No. 1 to 2017 Employee Stock Purchase Plan Exhibit 10.1 AMENDMENT NO. 1 TO 2017 EMPLOYEE STOCK PURCHASE PLAN OF APELLIS PHARMACEUTICALS, INC. The 2017 Employee Stock Purchase Plan (the “Plan”) of Apellis Pharmaceuticals, Inc. is hereby amended as follows: 1. Section 2(b) of the Plan is hereby deleted and a new Section 2(b) is inserted in lieu thereof which shall read as follows: “(b) they have been employed by the Company or a Designated S
November 2, 2020	10-Q	Quarterly Report - 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38276 APELLIS PHARMACEUTICALS, INC.
October 27, 2020	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 27, 2020 Apellis Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38276 27-1537290 (State or Other Jurisdiction of Incorporation) (Com
October 27, 2020	EX-99.1	Apellis and Sobi Enter Collaboration for Global EX-99.1 Exhibit 99.1 Apellis and Sobi Enter Collaboration for Global Co-development and Ex-US Commercialization of Systemic Pegcetacoplan in Rare Diseases with Urgent Need for New Treatments • Sobi obtains global co-development and exclusive ex-U.S. commercialization rights for systemic pegcetacoplan, a targeted C3 therapy • Apellis retains U.S. commercialization rights for systemic pegcetacoplan
July 30, 2020	10-Q	Quarterly Report - 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38276 APELLIS PHARMACEUTICALS, INC.
June 1, 2020	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 1, 2020 Apellis Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38276 27-1537290 (State or Other Jurisdiction of Incorporation) (Commiss
May 13, 2020	8-K	Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2020 Apellis Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38276 27-1537290 (State or Other Jurisdiction of Incorporation) (Commiss
May 7, 2020	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2020 Apellis Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38276 27-1537290 (State or Other Jurisdiction of Incorporation) (Commissi
May 7, 2020	EX-10.1	Form of Capped Call Transaction Confirmation EX-10.1 Exhibit 10.1 [Dealer] May 6, 2020 To: Apellis Pharmaceuticals, Inc. 100 Fifth Avenue Waltham, MA 02451 Attention: David Watson, General Counsel Telephone No.: (617) 977-5700 Re: Call Option Transaction The purpose of this letter agreement (this “Confirmation”) is to confirm the terms and conditions of the call option transaction entered into between [Dealer] (“Dealer”) and Apellis Pharmace
May 7, 2020	EX-99.1	Apellis Pharmaceuticals Announces Private Placement of Convertible Senior Notes EX-99.1 3 d922186dex991.htm EX-99.1 Exhibit 99.1 Apellis Pharmaceuticals Announces Private Placement of Convertible Senior Notes WALTHAM, Mass., May 7, 2020 (GLOBE NEWSWIRE) – Apellis Pharmaceuticals, Inc. (Nasdaq:APLS), a global biopharmaceutical company pioneering targeted C3 therapies, today announced that it had entered into subscription agreements with a number of institutional investors for
April 29, 2020	10-Q	Quarterly Report - 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38276 APELLIS PHARMACEUTICALS, INC.
April 22, 2020	DEFA14A	APLS / Apellis Pharmaceuticals, Inc. DEFA14A - - DEFA14A DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
April 22, 2020	DEF 14A	APLS / Apellis Pharmaceuticals, Inc. DEF 14A - - DEF 14A DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
April 6, 2020	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 2, 2020 Apellis Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38276 27-1537290 (State or Other Jurisdiction of Incorporation) (Commis
February 27, 2020	S-8	File No. 333-236708 As filed with the Securities and Exchange Commission on February 27, 2020 Registration No.
February 27, 2020	EX-21.1	Subsidiaries of the Registrant Exhibit 21.1 SUBSIDIARIES OF APELLIS PHARMACEUTICALS, INC. Subsidiary Jurisdiction of Incorporation or Organization Apellis Australia Pty Ltd. Australia Apellis Ireland Ltd. Ireland Apellis Switzerland GmbH Switzerland Apellis MA Securities Inc. United States
February 27, 2020	S-8	File No. 333-236710 As filed with the Securities and Exchange Commission on February 27, 2020 Registration No.
February 27, 2020	EX-99.1	2020 Inducement Stock Incentive Plan (filed as Exhibit 99.1 to the registrant’s Registration Statement on S-8 filed on February 27, 2020 (File No. 333-236710) and incorporated herein by reference) Exhibit 99.1 APELLIS PHARMACEUTICALS, INC. 2020 INDUCEMENT STOCK INCENTIVE PLAN 1. Purpose The purpose of this 2020 Inducement Stock Incentive Plan (the ?Plan?) of Apellis Pharmaceuticals, Inc., a Delaware corporation (the ?Company?), is to advance the interests of the Company?s stockholders by enhancing the Company?s ability to attract, retain and motivate persons who are expected to make importa
February 27, 2020	10-K	Annual Report - 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-38276 APELLIS PHARMAC
February 27, 2020	EX-4.4	Description of Securities Registered Under Section 12 of the Exchange Act Exhibit 4.4 DESCRIPTION OF SECURITIES REGISTERED UNDER SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following description of the common stock, par value $0.0001 per share (the “Common Stock”), of Apellis Pharmaceuticals, Inc. (“us,” “our,” “we” or the “Company”), which is the only security of the Company registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “
February 14, 2020	SC 13G/A	APLS / Apellis Pharmaceuticals, Inc. / Cormorant Asset Management, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* Apellis Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 037530106 (CUSIP Number) December 31, 2019 (Date of Event which Requires Filing of this Statement) Check the appropriate box to design
February 14, 2020	SC 13G/A	APLS / Apellis Pharmaceuticals, Inc. / Hillhouse Capital Advisors, Ltd. - APELLIS PHARMACEUTICALS, INC. Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Apellis Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value of $0.0001 per share (Title of Class of Securities) 03753U106 (CUSIP Number) December 31, 2019 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the r
February 10, 2020	SC 13G/A	APLS / Apellis Pharmaceuticals, Inc. / Wellington Management Group LLP - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* Apellis Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 03753U106 (CUSIP Number) January 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to whic
January 28, 2020	SC 13G	APLS / Apellis Pharmaceuticals, Inc. / Wellington Management Group LLP - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Apellis Pharmaceutic (Name of Issuer) Common Stock (Title of Class of Securities) 03753U106 (CUSIP Number) December 31, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sch
January 9, 2020	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 8, 2020 Apellis Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38276 27-1537290 (State or Other Jurisdiction of Incorporation) (Comm
January 9, 2020	EX-1.1	Underwriting Agreement, dated January 8, 2020, by and among the Company and Citigroup Global Markets Inc., J.P. Morgan Securities LLC and Evercore Group L.L.C. EX-1.1 Exhibit 1.1 Apellis Pharmaceuticals, Inc. 9,500,000 Shares Common Stock ($0.0001 par value per share) Underwriting Agreement New York, New York January 8, 2020 Citigroup Global Markets Inc. J.P. Morgan Securities LLC Evercore Group L.L.C. As Representatives of the several Underwriters, c/o Citigroup Global Markets Inc. 388 Greenwich Street New York, New York 10013 c/o J.P. Morgan Securities
January 9, 2020	424B5	CALCULATION OF REGISTRATION FEE Title of Each Class of Securities Offered Amount to be Registered(1) Maximum Offering Price Per Unit Maximum Aggregate Offering Price(1) Amount of Registration Fee(2) Common Stock, par value $0.0001 per share 10,925,00 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-235830 CALCULATION OF REGISTRATION FEE Title of Each Class of Securities Offered Amount to be Registered(1) Maximum Offering Price Per Unit Maximum Aggregate Offering Price(1) Amount of Registration Fee(2) Common Stock, par value $0.0001 per share 10,925,000 $37.00 $404,225,000 $52,468.41 (1) Assumes exercise in full of
January 9, 2020	EX-99.1	Apellis Pharmaceuticals Announces Pricing of Public Offering of Common Stock EX-99.1 Exhibit 99.1 Apellis Pharmaceuticals Announces Pricing of Public Offering of Common Stock WALTHAM Mass., January 8, 2020 (GLOBE NEWSWIRE) – Apellis Pharmaceuticals, Inc. (Nasdaq:APLS), a global biopharmaceutical company pioneering targeted C3 therapies, today announced the pricing of its underwritten public offering of 9.5 million shares of its common stock at a public offering price of $3
January 7, 2020	S-3ASR	APLS / Apellis Pharmaceuticals, Inc. S-3ASR - - S-3ASR S-3ASR Table of Contents As filed with the Securities and Exchange Commission on January 7, 2020 Registration No.
January 7, 2020	EX-4.4	Form of Subordinated Indenture EX-4.4 Exhibit 4.4 APELLIS PHARMACEUTICALS, INC. and Trustee INDENTURE Dated as of SUBORDINATED DEBT SECURITIES CROSS-REFERENCE TABLE1 Section of Trust Indenture Act of 1939, as amended Section of Indenture 310(a) 6.09 310(b) 6.08 6.10 310(c) Inapplicable 311(a) 6.13 311(b) 6.13 311(c) Inapplicable 312(a) 4.01 4.04 312(b) 4.04(c) 312(c) 4.04(c) 313(a) 4.03 313(b) 4.03 313(c) 4.03 313(d) 4.03 314(a
January 7, 2020	EX-4.6	Form of Subordinated Note EX-4.6 5 d861846dex46.htm EX-4.6 Exhibit 4.6 Form of Subordinated Note (FACE OF SECURITY) [Each Global Security shall bear substantially the following legend: UNLESS AND UNTIL IT IS EXCHANGED IN WHOLE OR IN PART FOR SECURITIES IN DEFINITIVE REGISTERED FORM, THIS SECURITY MAY NOT BE TRANSFERRED EXCEPT AS A WHOLE BY THE DEPOSITARY TO A NOMINEE OF THE DEPOSITARY OR BY A NOMINEE OF THE DEPOSITARY TO T
January 7, 2020	424B5	SUBJECT TO COMPLETION, DATED JANUARY 7, 2020 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-235830 The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these securities has been filed with the Securities and Exchange Commission and is effective. This preliminary prospectus supplement and the accompanying prospectus are not an offer to
January 7, 2020	8-K	Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 7, 2020 Apellis Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38276 27-1537290 (State or Other Jurisdiction of Incorporation) (Comm
January 7, 2020	EX-4.3	Form of Senior Indenture EX-4.3 2 d861846dex43.htm EX-4.3 Exhibit 4.3 APELLIS PHARMACEUTICALS, INC. and Trustee INDENTURE Dated as of SENIOR DEBT SECURITIES CROSS-REFERENCE TABLE1 Section of Trust Indenture Act of 1939, as amended Section of Indenture 310(a) 6.09 310(b) 6.08 6.10 310(c) Inapplicable 311(a) 6.13 311(b) 6.13 311(c) Inapplicable 312(a) 4.01 4.04 312(b) 4.04(c) 312(c) 4.04(c) 313(a) 4.03 313(b) 4.03 313(c) 4.
January 7, 2020	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 7, 2020 Apellis Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38276 27-1537290 (State or Other Jurisdiction of Incorporation) (Comm
January 7, 2020	EX-4.5	Form of Senior Note EX-4.5 4 d861846dex45.htm EX-4.5 Exhibit 4.5 Form of Senior Note (FACE OF SECURITY) [Each Global Security shall bear substantially the following legend: UNLESS AND UNTIL IT IS EXCHANGED IN WHOLE OR IN PART FOR SECURITIES IN DEFINITIVE REGISTERED FORM, THIS SECURITY MAY NOT BE TRANSFERRED EXCEPT AS A WHOLE BY THE DEPOSITARY TO A NOMINEE OF THE DEPOSITARY OR BY A NOMINEE OF THE DEPOSITARY TO THE DEP
November 5, 2019	10-Q	Quarterly Report - 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38276 APELLIS PHARMACEUTICALS, INC.
November 5, 2019	EX-10.1	Third Amendment to Lease, dated September 25, 2019, by and between Registrant and NWALP PHOP Property Owner LLC. Exhibit 10.1 THIRD AMENDMENT TO LEASE This THIRD AMENDMENT TO LEASE (this “Amendment”) is entered into this 25th day of September, 2019 (the “Effective Date”) by and between NWALP PHOP Property Owner LLC, a Delaware limited liability company (the “Landlord”), and Apellis Pharmaceuticals, Inc., a Delaware corporation (the “Tenant”). W I T N E S S E T H: WHEREAS, the Landlord and the Tenant entered
October 7, 2019	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 1, 2019 Apellis Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38276 27-1537290 (State or Other Jurisdiction of Incorporation) (Comm
October 7, 2019	EX-10.1	Apellis Pharmaceuticals, Inc. Executive Separation Benefits and Retention Plan. EX-10.1 Exhibit 10.1 Apellis Pharmaceuticals, Inc. Executive Separation Benefits and Retention Plan 1. Establishment of Plan. Apellis Pharmaceuticals, Inc., a Delaware corporation (the “Company”), hereby establishes an unfunded separation benefits and retention plan (the “Plan”) that is intended to be a welfare benefit plan within the meaning of Section 3(1) of ERISA. The Plan is in effect for Cov
October 4, 2019	POS AM	APLS / Apellis Pharmaceuticals, Inc. POS AM - - POS AM POS AM 1 d768866dposam.htm POS AM Table of Contents As filed with the Securities and Exchange Commission on October 4, 2019 Registration No. 333-229091 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 3 TO FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Apellis Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Its C
October 4, 2019	EX-1.2	Amended and Restated Equity Distribution Agreement, dated October 4, 2019, by and among the Registrant and Citigroup Global Markets Inc. and Jefferies LLC EX-1.2 2 d768866dex12.htm EX-1.2 Exhibit 1.2 Apellis Pharmaceuticals, Inc. $150,000,000 Shares Common Stock ($0.0001 par value per share) Amended and Restated Equity Distribution Agreement October 4, 2019 Citigroup Global Markets Inc. 388 Greenwich Street New York, New York, 10013 Jefferies LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: Reference is made to the Equity Distri
September 16, 2019	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 11, 2019 Apellis Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38276 27-1537290 (State or Other Jurisdiction of Incorporation) (C
September 16, 2019	EX-4.1	Indenture (including form of Note), dated as of September 16, 2019, by and between Apellis Pharmaceuticals, Inc. and U.S. Bank National Association, as trustee EX-4.1 Exhibit 4.1 APELLIS PHARMACEUTICALS, INC. AND U.S. BANK NATIONAL ASSOCIATION, as Trustee INDENTURE Dated as of September 16, 2019 3.500% Convertible Senior Notes due 2026 TABLE OF CONTENTS PAGE ARTICLE 1 DEFINITIONS Section 1.01. Definitions 1 Section 1.02. References to Interest 13 ARTICLE 2 ISSUE, DESCRIPTION, EXECUTION, REGISTRATION AND EXCHANGE OF NOTES Section 2.01. Designation and Amo
September 16, 2019	EX-10.1	Form of Capped Call Transaction Confirmation EX-10.1 3 d802733dex101.htm EX-10.1 Exhibit 10.1 [Dealer] September 11, 2019 To: Apellis Pharmaceuticals, Inc. 6400 Westwind Way, Suite A Crestwood, KY 40014 Attention: David Watson, General Counsel Re: Base Call Option Transaction The purpose of this letter agreement (this “Confirmation”) is to confirm the terms and conditions of the call option transaction entered into between [Dealer] (“Dealer”
September 16, 2019	EX-99.1	Apellis Pharmaceuticals Announces Closing of Offering of Convertible Senior Notes EX-99.1 Exhibit 99.1 Apellis Pharmaceuticals Announces Closing of Offering of Convertible Senior Notes CRESTWOOD, Ky., and WALTHAM, Mass., September 16, 2019 (GLOBE NEWSWIRE) – Apellis Pharmaceuticals, Inc. (Nasdaq:APLS), a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, today annou
September 12, 2019	EX-99.1	Apellis Pharmaceuticals Announces Pricing of Offering of Convertible Senior Notes EX-99.1 2 d801818dex991.htm EX-99.1 Exhibit 99.1 Apellis Pharmaceuticals Announces Pricing of Offering of Convertible Senior Notes CRESTWOOD, Ky., and WALTHAM, Mass., September 12, 2019 (GLOBE NEWSWIRE) – Apellis Pharmaceuticals, Inc. (Nasdaq:APLS), a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the co
September 12, 2019	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 11, 2019 Apellis Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38276 27-1537290 (State or Other Jurisdiction of Incorporation) (C
September 11, 2019	EX-99.1	Apellis Pharmaceuticals Announces Proposed Private Offering of $200 Million of Convertible Senior Notes EX-99.1 Exhibit 99.1 Apellis Pharmaceuticals Announces Proposed Private Offering of $200 Million of Convertible Senior Notes CRESTWOOD, Ky., and WALTHAM, Mass., September 11, 2019 (GLOBE NEWSWIRE) – Apellis Pharmaceuticals, Inc. (Nasdaq:APLS), a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the compleme
September 11, 2019	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 11, 2019 Apellis Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38276 27-1537290 (State or Other Jurisdiction of Incorporation) (C
July 31, 2019	EX-10.1	Amendment, dated as of June 7, 2019, to the Development Funding Agreement, dated as of February 28, 2019 by and between the Registrant and SFJ Pharmaceuticals XI, L.P. Exhibit 10.1 Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) would likely cause competitive harm to the Company, if publicly disclosed. Double asterisks denote omissions. AMENDMENT TO DEVELOPMENT FUNDING AGREEMENT This Amendment to Development Funding Agreement (“Amendment”), made effective as of June 7, 2019 (the “Amendment Date”), en
July 31, 2019	10-Q	Quarterly Report - 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38276 APELLIS PHARMACEUTICALS, INC.
July 31, 2019	EX-10.2	Second Amendment to Lease, dated June 5, 2019, by and between Registrant and NWALP PHOP Property Owner LLC. EX-10.2 3 apls-ex102184.htm EX-10.2 SECOND AMENDMENT Exhibit 10.2 SECOND AMENDMENT TO LEASE This SECOND AMENDMENT TO LEASE (this “Amendment”) is entered into this 5th day of June, 2019 (the “Effective Date”) by and between NWALP PHOP Property Owner LLC, a Delaware limited liability company (the “Landlord”), and Apellis Pharmaceuticals, Inc., a Delaware corporation (the “Tenant”). W I T NE S S E T
June 21, 2019	8-K	Submission of Matters to a Vote of Security Holders 8-K 1 d766897d8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 18, 2019 Apellis Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38276 27-1537290 (State or Other Jurisdiction
June 10, 2019	8-K	Entry into a Material Definitive Agreement 8-K 1 d763096d8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 7, 2019 Apellis Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38276 27-1537290 (State or Other Jurisdiction o
May 24, 2019	SC 13G/A	APLS / Apellis Pharmaceuticals, Inc. / Morningside Venture Investments Ltd - SC 13G/A Passive Investment OMB APPROVAL UNITED STATES OMB Number: 3235-0145 SECURITIES AND EXCHANGE COMMISSION Expires: February 28, 2009 Washington, D.
May 24, 2019	EX-99.1	JOINT FILING AGREEMENT EXHIBIT 99.1 JOINT FILING AGREEMENT The undersigned, being duly authorized thereunder, hereby execute this agreement as an exhibit to this Schedule 13G to evidence the agreement of the below-named parties, in accordance with the rules promulgated pursuant to the Securities Exchange Act of 1934, to file this Schedule 13G (including amendments thereto) jointly on behalf of each such party. MORNINGSI
May 7, 2019	10-Q	Quarterly Report - 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38276 APELLIS PHARMACEUTICALS, INC.
May 7, 2019	EX-10.2	Standard Office Lease, dated as of March 29, 2019, by and between the Registrant and Geary-Market Investment Company, Ltd. Exhibit 10.2 STANDARD OFFICE LEASE Between Geary-Market Investment Company, Ltd., a California corporation (“Landlord”) And Apellis Pharmaceuticals, Inc. a Delaware corporation (“Tenant”) 09338.008 2450031v1 ActiveUS 172034323v.3 STANDARD OFFICE LEASE This Standard Office Lease (“Lease”) is made as of March 29, 2019 by and between Geary-Market Investment Company, Ltd., a California corporation (“L
May 7, 2019	EX-10.3	Offer Letter, dated as of April 13, 2018, by and between the Registrant and Lukas Scheibler Exhibit 10.3 April 13, 2018 Dr. Lukas Scheibler 469 Saddle Horn Ln Telluride,CO, 81435 VIA EMAIL Dear Lukas, We are pleased to extend you an offer to join Apellis Pharmaceuticals, Inc. (the “Company”) as its Executive Vice President of Research and Translational Medicine on the terms and conditions set forth in this letter. Subject to satisfaction of the conditions described in this letter, you wi
May 7, 2019	EX-10.1	Development Funding Agreement, dated as of February 28, 2019, by and between the Registrant and SFJ Pharmaceuticals XI, L.P. Exhibit 10.1 Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) would likely cause competitive harm to the Company, if publicly disclosed. Double asterisks denote DEVELOPMENT FUNDING AGREEMENT This Development Funding Agreement (“Agreement”), made effective as of February 28, 2019 (the “Effective Date”), is by and between Apellis Pharmace
April 30, 2019	DEFA14A	APLS / Apellis Pharmaceuticals, Inc. DEFA14A DEFA14A DEFA14A 1 d634641ddefa14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as
April 30, 2019	DEF 14A	definitive proxy statement DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
April 12, 2019	EX-16.1	Letter from Ernst & Young LLP to the SEC, dated April 11, 2019, regarding the statements made in this Current Report on Form 8-K. EX-16.1 Exhibit 16.1 Ernst & Young LLP Suite 2400 400 West Market Street Louisville, KY 40202 Tel: +1 502 585 1400 Fax: +1 502 584 4221 ey.com April 11, 2019 Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Ladies and Gentlemen: We have read Item 4.01 of Form 8-K dated April 8, 2019, of Apellis Pharmaceuticals, Inc. and are in agreement with the statements contained in th
April 12, 2019	8-K	Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 8, 2019 Apellis Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38276 27-1537290 (State or Other Jurisdiction of Incorporation) (Co
March 22, 2019	SC 13G/A	APLS / Apellis Pharmaceuticals, Inc. / Morningside Venture Investments Ltd - SC 13G/A Passive Investment UNITED STATES OMB APPROVAL SECURITIES AND EXCHANGE COMMISSION OMB Number: 3235-0145 Washington, D.
March 22, 2019	EX-99.1	JOINT FILING AGREEMENT EXHIBIT 99.1 JOINT FILING AGREEMENT The undersigned, being duly authorized thereunder, hereby execute this agreement as an exhibit to this Schedule 13G to evidence the agreement of the below-named parties, in accordance with the rules promulgated pursuant to the Securities Exchange Act of 1934, to file this Schedule 13G (including amendments thereto) jointly on behalf of each such party. MORNINGSI
March 13, 2019	EX-99.1	JOINT FILING AGREEMENT EX-99.1 2 a19-63051ex99d1.htm EX-99.1 EXHIBIT 99.1 JOINT FILING AGREEMENT The undersigned, being duly authorized thereunder, hereby execute this agreement as an exhibit to this Schedule 13G to evidence the agreement of the below-named parties, in accordance with the rules promulgated pursuant to the Securities Exchange Act of 1934, to file this Schedule 13G (including amendments thereto) jointly o
March 13, 2019	SC 13G/A	APLS / Apellis Pharmaceuticals, Inc. / Morningside Venture Investments Ltd - SC 13G/A Passive Investment UNITED STATES OMB APPROVAL SECURITIES AND EXCHANGE COMMISSION OMB Number: 3235-0145 Washington, D.
March 7, 2019	424B5	6,000,000 Shares Common Stock 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-229091 PROSPECTUS SUPPLEMENT (To Prospectus Dated February 26, 2019) 6,000,000 Shares Common Stock We are offering 6,000,000 shares of our common stock in this offering. Our common stock is listed on the Nasdaq Global Select Market under the symbol “APLS.” The last reported sale price of our common stock on the Nasdaq Gl
March 7, 2019	EX-1.1	Underwriting Agreement, dated March 6, 2019, by and among the Company and Citigroup Global Markets Inc., J.P. Morgan Securities LLC and Cowen and Company, LLC EX-1.1 Exhibit 1.1 EXECUTION COPY Apellis Pharmaceuticals, Inc. 6,000,000 Shares Common Stock ($0.0001 par value per share) Underwriting Agreement New York, New York March 6, 2019 Citigroup Global Markets Inc. J.P. Morgan Securities LLC Cowen and Company, LLC As Representatives of the several Underwriters, c/o Citigroup Global Markets Inc. 388 Greenwich Street New York, New York 10013 c/o J.P. Mor
March 7, 2019	EX-99.1	Apellis Pharmaceuticals Announces Pricing of Public Offering of Common Stock EX-99.1 4 d714508dex991.htm EX-99.1 Exhibit 99.1 Apellis Pharmaceuticals Announces Pricing of Public Offering of Common Stock WALTHAM Mass., and CRESTWOOD, Ky., March 7, 2019 (GLOBE NEWSWIRE) – Apellis Pharmaceuticals, Inc., (Nasdaq:APLS) a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement sy
March 7, 2019	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events 8-K 1 d714508d8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 6, 2019 Apellis Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38276 27-1537290 (State or Other Jurisdiction
March 6, 2019	424B5	SUBJECT TO COMPLETION, DATED MARCH 6, 2019 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-229091 The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these securities has been filed with the Securities and Exchange Commission and is effective. This preliminary prospectus supplement and the accompanying prospectus are not an offer to
March 4, 2019	8-K	Other Events Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 4, 2019 Apellis Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38276 27-1537290 (State or Other Jurisdiction of Incorporation
February 28, 2019	8-K	Entry into a Material Definitive Agreement 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2019 Apellis Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38276 27-1537290 (State or Other Jurisdiction of Incorporation)
February 26, 2019	10-K	APLS / Apellis Pharmaceuticals, Inc. 10-K (Annual Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-38276 APELLIS PHARMAC
February 26, 2019	EX-21.1	Subsidiaries of the Registrant Exhibit 21.1 SUBSIDIARIES OF APELLIS PHARMACEUTICALS, INC. Subsidiary Jurisdiction of Incorporation or Organization Apellis Australia Pty Ltd. Australia Apellis Ireland Ltd. Ireland
February 26, 2019	POS AM	APLS / Apellis Pharmaceuticals, Inc. POS AM POS AM 1 d704337dposam.htm POS AM Table of Contents As filed with the Securities and Exchange Commission on February 26, 2019 Registration No. 333-229091 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 2 TO FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Apellis Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Its

IT:1APLS	€ 24.26
DE:1JK	€ 23.90

APLS / Apellis Pharmaceuticals, Inc. - Pengajuan SECLaporan Tahunan, Pernyataan Proksi

Mga Batayang Estadistika

SEC Filings

SEC Filings (Chronological Order)

Other Listings